Drug reference

Ravulizumab

Monoclonal Antibody · Treatment for Paroxysmal Nocturnal Hemoglobinuria

Also known as Ultomiris

Monoclonal AntibodyTreatment for Paroxysmal Nocturnal Hemoglobinuria

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Ravulizumab is a monoclonal antibody that binds to the C5 component of complement, blocking its cleavage. This action disrupts the lytic cascade, preventing the formation of the membrane attack complex. By inhibiting complement activation, ravulizumab prevents the lysis of host red blood cells in conditions such as paroxysmal nocturnal hemoglobinuria.

Indications

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Dosing

Adult: range of doses that are generally regarded as being suitable for adults. Complementary and alternative medicine Prescribing unlicensed medicines An increasing amount of information on complementary and alternative medicine is becoming available.…